Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The group has obtained approval from the China National Drug Administration (CFDA) for drug production registration for the oral solution of nimodipine (10ml: 60mg), which is a Class 3 chemical, and is deemed to have passed the consistency evaluation.

Nimodipine oral solution is mainly used in adult patients with subarachnoid hemorrhage (SAH) with ruptured intracranial cystic aneurysm to improve the neurological prognosis of patients by reducing the incidence and severity of ischemic nerve damage. The Group's nimodipine APIs have been approved by the State Drug Administration and registered as APIs for use in marketed formulations. This time, the nimodipine oral solution formulation was approved, enabling integrated collaboration of active drug formulations and further enriching the Group's product portfolio in the fields of cardiovascular and neurological diseases.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.